🔗 Share this article

Ex-government leader Rishi Sunak has strengthened his appeal for a focused testing initiative for prostate cancer.

In a recent discussion, he expressed being "persuaded of the critical importance" of introducing such a initiative that would be economical, achievable and "save numerous lives".

His statements come as the National Screening Advisory Body reevaluates its determination from half a decade past declining to suggest regular testing.

Media reports suggest the authority may uphold its existing position.

Olympic Champion Contributes Voice to Campaign

Champion athlete Sir Chris Hoy, who has advanced prostate cancer, wants younger men to be tested.

He suggests reducing the minimum age for accessing a prostate-specific antigen blood test.

Currently, it is not automatically provided to healthy individuals who are below fifty.

The prostate-specific antigen screening remains debated though. Readings can elevate for causes other than cancer, such as inflammation, leading to misleading readings.

Opponents maintain this can cause unwarranted procedures and complications.

Focused Testing Proposal

The proposed testing initiative would target men aged 45–69 with a hereditary background of prostate cancer and African-Caribbean males, who face increased susceptibility.

This group comprises around over a million individuals in the United Kingdom.

Organization calculations propose the programme would necessitate £25 million a year - or about £18 per person per patient - similar to bowel and breast cancer examination.

The estimate includes 20% of qualified individuals would be contacted yearly, with a nearly three-quarters response rate.

Diagnostic activity (scans and tissue samples) would need to expand by 23%, with only a moderate increase in NHS staffing, as per the report.

Medical Professionals Response

Various healthcare professionals remain uncertain about the effectiveness of testing.

They assert there is still a possibility that individuals will be treated for the disease when it is not absolutely required and will then have to experience side effects such as urinary problems and sexual performance issues.

One respected urological professional remarked that "The issue is we can often find abnormalities that doesn't need to be addressed and we end up causing harm...and my concern at the moment is that harm to benefit equation needs adjustment."

Individual Experiences

Personal stories are also influencing the debate.

A particular case concerns a man in his mid-sixties who, after asking for a blood examination, was identified with the condition at the age of 59 and was told it had progressed to his pelvis.

He has since undergone chemo treatment, beam therapy and endocrine treatment but remains incurable.

The man endorses testing for those who are genetically predisposed.

"This is essential to me because of my children – they are approaching middle age – I want them screened as soon as possible. If I had been screened at fifty I am sure I would not be in the situation I am today," he said.

Future Actions

The Medical Screening Authority will have to weigh up the evidence and arguments.

While the new report indicates the implications for staffing and accessibility of a screening programme would be feasible, others have contended that it would take scanning capacity away from individuals being cared for for different health issues.

The ongoing debate underscores the complicated trade-off between timely diagnosis and likely unnecessary management in prostate cancer care.